Filing Flows › Krystal Biotech (KRYS) › Q2 2026 › vs Q2 2025
Krystal Biotech (KRYS) Q2 2026 vs Q2 2025 (year over year)
Krystal Biotech's revenue rose $23.2M (+24%) from $96.0M in Q2 2025 to $119M in Q2 2026. Operating margin 49.0% against 41.0% (+8.0 pts).
Krystal Biotech, Q2 2026: revenue $119M (+24% year over year), operating margin 49.0%, net earnings $54.8M, operating cash flow $74.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 49.0% | 41.0% | +8.0 pts |
| Net margin | 45.9% | 39.9% | +6.0 pts |
| Free cash flow margin | 59.7% | 52.9% | +6.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $119M | $96.0M | $23.2M | +24% |
| Other income, net | $7.7M | $7.4M | $286K | +4% |
| Operating profit | $58.4M | $39.4M | $19.0M | +48% |
| Costs & expenses | $60.8M | $56.6M | $4.2M | +7% |
| Pre-tax earnings | $66.1M | $46.8M | $19.3M | +41% |
| Research & development | $14.5M | $14.4M | $108K | +0.7% |
| SG&A | $39.9M | $35.1M | $4.8M | +14% |
| Other operating costs | $6.4M | $7.2M | −$728K | -10% |
| Net earnings | $54.8M | $38.3M | $16.4M | +43% |
| Income tax | $11.3M | $8.4M | $2.9M | +34% |
| Depreciation | $1.4M | $1.3M | $100K | +8% |
| Share-based compensation | $14.2M | $14.1M | $37K | +0.3% |
| Working capital & other | $4.5M | −$1.0M | $5.5M | — |
| Operating cash flow | $74.8M | $52.7M | $22.1M | +42% |
| Free cash flow (OCF − capex) | $71.2M | $50.8M | $20.4M | +40% |
| Capital expenditures | $3.6M | $1.9M | $1.7M | +87% |
Questions
How much did Krystal Biotech's revenue grow year over year in Q2 2026?
Krystal Biotech's revenue rose $23.2M (+24%) from $96.0M in Q2 2025 to $119M in Q2 2026. Operating margin 49.0% against 41.0% (+8.0 pts).